News Release

Mallinckrodt plc to Report Second Quarter Results on May 8, 2014

DUBLIN--(BUSINESS WIRE)--Apr. 21, 2014-- Mallinckrodt plc (NYSE: MNK) will report second quarter results on Thursday, May 8, 2014. The company will hold a conference call for investors from 7:30-8:00am, U.S. Eastern Time. Shortly after the earnings call, the company will hold a separate “live” fireside chat question and answer session for investors at the St. Regis New York, 2 East 55th Street at 5th Avenue in New York City, which will also be available by conference call.

Those wishing to attend the fireside chat may arrive at the St. Regis at 7:30am and proceed to the St. Regis Roof Meeting room, where questions will be taken both live and by phone beginning at 8:15am.

The calls can be accessed in three ways.

  • At the Mallinckrodt website:
  • By telephone: For both “listen-only” participants and those who wish to take part in the question-and-answer portion of the second session, the telephone dial-in number in the U.S. (877) 359-9508. For participants outside the U.S., the dial-in number is (224) 357-2393. The conference I.D. (access number) for the earnings call at 7:30am is 30870215 and the I.D. for the Fireside Chat is 32627753
  • Through an audio replay: A replay of the call will be available by 4pm U.S. Eastern Time on May 8, 2014, and ending at 11:59pm/ U.S. Eastern Time on May 15, 2014. The dial-in number for U.S. participants is (855) 859-2056. For participants outside the U.S., the replay dial-in number is (404) 537-3406. The replay conference I.D. for the earnings call is 30870215 and the conference I.D. to hear the Fireside Chat is 32627753

Those who listen to the earnings call or webcast will need to call back to the same number noted above to participate in the fireside chat. Please note the two segments have separate conference I.D. numbers.

If you wish to join the live fireside chat at the St. Regis New York, please RSVP to to ensure you are registered.


Mallinckrodt is a global specialty pharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. The company’s core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. The company’s Specialty Pharmaceuticals segment includes branded and specialty generic drugs and active pharmaceutical ingredients, and the Global Medical Imaging segment includes contrast media and nuclear imaging agents. Mallinckrodt has approximately 5,500 employees worldwide and a commercial presence in approximately 65 countries. The company’s fiscal 2013 revenue totaled $2.2 billion. To learn more about Mallinckrodt, visit

Source: Mallinckrodt plc

Mallinckrodt plc
John Moten, 314-654-6650
Vice President, Investor Relations
Lynn Phillips, 314-654-3263
Manager, Communications
Meredith Fischer, 314-654-6595
Senior Vice President, Communications